TrialThe British journal of dermatology2021

Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.

D F Murrell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.